‘No evidence’ BioNTech jabs need to be adapted against COVID-19 variants yet: Company

Published: Updated:

BioNTech on Monday said there was “no evidence” its jabs need to be adapted against coronavirus variants yet.

For more coronavirus news, visit our dedicated page.

Earlier in the day, the company said it would build a factory in Singapore that could produce hundreds of millions of doses of vaccines based on its mRNA technology per year in southeast Asia.

Construction of the manufacturing plant and a regional headquarters in Singapore will start this year, and the site could become operational by 2023, the German company said in a statement.

Read more:

COVID-19 jab maker BioNTech to build factory in Singapore

GAVI in talks with China’s Sinopharm, others to expand COVAX reach